Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Olaparib delays progression but has not lengthened overall survival, and the best duration of maintenance is unknown.
Somatic and non-BRCA repair gene alterations respond unpredictably, and there is no validated homologous recombination deficiency test for the pancreas.
Reversion mutations restore repair and defeat both platinum and PARP inhibitors.
Nothing recorded yet.
Nothing recorded yet.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance atlas · Lines of therapy.
Whether unaffected carriers benefit from pancreatic surveillance is still being established.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
PREOPANC-1 5-year OS 20.
A milestone in how this cancer is treated.
PFS HR 0.
A milestone in how this cancer is treated.
OS 54.